NAGE - NASDAQ
NB
Niagen Bioscience Inc
NAGE·NASDAQ
$3.46
-2.1%HealthcareBiotechnology
Niagen Bioscience Inc is a bioscience company dedicated to healthy aging. The Company leads research on nicotinamide adenine dinucleotide.
At a Glance
Live SnapshotMarket Cap$275.97M
EPS0.2200
P/E Ratio15.75
Earnings Date08/05/2026
nage
Operating Expenses
Last Annual Value
68.89M
3-Year CAGR
4%
5-Year CAGR
5%
10-Year CAGR
22%
NB
Niagen Bioscience Inc Competitors Analysis of Operating Expenses
NAGE · NASDAQ
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
 Niagen Bioscience Inc NASDAQ:NAGE | 68.89M | 6.9% | 0.1% | 17.9% | |
 Prothena Corporation plc NASDAQ:PRTA | 190.54M | -12.3% | 8.2% | 1.7% | |
 Akebia Therapeutics, Inc. NASDAQ:AKBA | 173.24M | 1.3% | -15.2% | 2.3% | |
 Ventyx Biosciences, Inc. NASDAQ:VTYX | 148.45M | -10.6% | 17.2% | N/A | |
 Keros Therapeutics, Inc. NASDAQ:KROS | 171.93M | 0.4% | 17.6% | N/A | |
 REGENXBIO Inc. NASDAQ:RGNX | 311.34M | -1.0% | 3.8% | 16.3% | |
 Olema Pharmaceuticals, Inc. NASDAQ:OLMA | 178.70M | 19.4% | 20.1% | N/A | |
 Corvus Pharmaceuticals, Inc. NASDAQ:CRVS | 42.87M | 22.3% | 2.1% | 1.5% | |
 KalVista Pharmaceuticals, Inc. NASDAQ:KALV | 239.38M | 29.2% | 70.5% | 30.0% | |
 Rigel Pharmaceuticals, Inc. NASDAQ:RIGL | 149.19M | 4.6% | -1.5% | 5.2% | |
 Zevra Therapeutics, Inc. NASDAQ:ZVRA | 94.22M | 8.3% | 37.9% | 10.6% |
NB
Niagen Bioscience Inc Fair Value Envelope
NAGE · NASDAQ
Related Guides
Continue your NAGE research with focused valuation guides.
Research Paths
1
Snapshot
Start with context, operating signals, and key market metrics.
2
Value Model
Stress test fair value across bear, base, and bull assumptions.
3
Statements
Validate revenue quality, margins, and balance sheet durability.
4
Earnings Call
Read management commentary and compare it with reported outcomes.
5
Dividends
Check payout sustainability and long-term distribution behavior.
6
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.